Acute Liver Injury in Patients Hospitalized with COVID-19
| Autor: | Lindsay A. Sobotka, Don C. Rockey, Michael L. Volk, B. Joseph Elmunzer, James Philip G. Esteban |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Physiology medicine.medical_treatment Outcomes Transaminase Internal medicine Intensive care Alkaline phosphatase medicine Extracorporeal membrane oxygenation Humans Leukocytosis Retrospective Studies Liver injury Mechanical ventilation Hepatitis SARS-CoV-2 business.industry Gastroenterology COVID-19 Alanine Transaminase Bilirubin Liver Failure Acute Hepatology medicine.disease Hospitalization Liver Original Article medicine.symptom Complication business Acute liver failure |
| Zdroj: | Digestive Diseases and Sciences |
| ISSN: | 1573-2568 0163-2116 |
| Popis: | Introduction The prevalence and significance of acute liver injury in patients with COVID-19 are poorly characterized. Methods Patients with confirmed COVID-19 who were hospitalized in geographically diverse medical centers in North America were included. Demographics, symptoms, laboratory data results, and outcomes were recorded. Linear and logistic regression identified factors associated with liver injury, in-hospital mortality, and length of stay (LOS). Results Among 1555 patients in the cohort, most (74%) had an elevated alanine aminotransferase (ALT) during hospitalization, which was very severe (> 20 × upper limit of normal [ULN]) in 3%. Severe acute liver injury (ALI) was uncommon, occurring in 0.1% on admission and 2% during hospitalization. No patient developed acute liver failure (ALF). Higher ALT was associated with leukocytosis (per mL3) (β 10.0, 95% confidence interval (CI) 6.7–12.6, p 20 × ULN (unadjusted OR 6.0, 95%CI 3.1–11.5, p 3 × ULN (unadjusted OR 4.4, 95%CI 2.5–7.7, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink